124. Candida haemulonii and Candida auris: Emerging Multidrug Resistant Species with Distinct Virulence and Epidemiological Characteristics
Session: Oral Abstract Session: Epidemiology and Outcomes in Mycology
Thursday, October 27, 2016: 11:30 AM
Room: 288-290
Background:

Candida haemulonii and Candida auris are recently described, closely related drug-resistant Candidaspecies. Little is known about the pathogenicity and epidemiological characteristics of these species.

Methods:

We reviewed Candidaclinical isolates recovered from 1/2008 through 12/2015 at the Tel Aviv Medical Center. Species identification was done using ITS1-ITS2 and D1/D2 LSU PCR and sequencing. We determined susceptibility to antifungals, genetic relatedness and efflux transporter activity. Virulence was assessed by intravenous infection of BALB/c mice immunosuppressed with cyclophosphamide.

Results:

Thirty-nine patient-unique isolates were identified as C. haemulonii by Vitek 2, of which 21 (54%) were from patients receiving care at a peripheral vascular disease outpatient clinic. Predisposing factors were diabetes mellitus type 2, end-stage renal disease, use of topical azoles on wounds and interpatient contact. Isolates were recovered from wounds (21), urine (11), blood (5), and vascular catheter (2). Of 9 isolates available for microbiological analysis, all 5 blood isolates were identified by sequencing as C. auris, whereas 4 non-invasive isolates were identified as C. haemulonii. C. auris, but not C. haemulonii, was thermotolerant at 37-40⁰C. C. auris was highly lethal in immunosuppressed mice, whereas C. haemulonii was avirulent in this model (log-rank test for survival, P<0.001). C. auris isolates were closely related to each other and phylogenetically distinct from isolates recovered in East Asia and South Africa. All isolates exhibited high MIC for fluconazole (MIC50, [range]), 32 mcg/mL (16-64 mcg/mL), anidulafungin, 8 mcg/mL (4-8 mcg/mL), and amphotericin B, 2 mcg/mL (1-2 mcg/mL). Transmembrane efflux activity was ~3 times that observed with C. glabrata.

Conclusion:

These are the first reported cases of clinical infection with C. auris and C. haemulonii in Israel. C. auris appears to be more virulent than C. haemulonii. C. haemulonii is transmitted efficiently among patients, suggesting a need for infection control measures. The emergence of these multidrug resistant Candida species warrants enhanced vigilance.

Talya Finn, MD1, Anna Novikov, MSc1, Shiri Zakin, PhD2, Edna Bash, MSc3, Judith Berman, PhD2 and Ronen Ben-Ami, MD1, (1)Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, (2)Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel, (3)Clinical Microbiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Disclosures:

T. Finn, None

A. Novikov, None

S. Zakin, None

E. Bash, None

J. Berman, None

R. Ben-Ami, Pfizer: Scientific Advisor , Consulting fee
Merck: Scientific Advisor , Consulting fee
Neopharm: Scientific Advisor , Consulting fee
Teva pharmaceuticals: Scientific Advisor , Consulting fee

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.